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Introduction 
Vaccines are the main option to prevent most infectious diseases, 
pneumococcal infections being one of the most important public 
health issues in the world [1,2]. The existing pneumococcal vaccines, 
capsular polysaccharide pneumococcal vaccines (PPV) and protein-
polysaccharide conjugate pneumococcal vaccines (PCV), have failed to 
prevent pneumococcal infections because the former are not effective 
in at-risk populations and the latter are too expensive to be used in 
developing countries. Pneumococcal proteins conserved among 
various serotypes have been evaluated and represent a new alternative 
for the development of protein-based pneumococcal vaccines (PbPVs) 
[3,4], but at present no PbPVs have been licensed. In addition, while 
S. pneumoniae enters the body by the nasal route, all vaccines are 
administered by the parenteral pathway and induce a good specific 
humoral response at the systemic level but not in mucosa. A crucial 
topic in the development of a pneumococcal vaccine is the selection 
of appropriate adjuvants that can enhance both the humoral and the 
cellular immune response. The most important consideration in the 
selection of an appropriate adjuvant for use in human vaccines is its 
biosafety and the only adjuvants approved for human use are aluminum 
salts. These adjuvants, which are used in parenteral vaccines to increase 
the titer of specific antibodies, are not the optimal adjuvants to induce 
CD4+ Th1 cells or cytotoxic (T or NK cells) immune responses, which 
are very important in the control of various pathogens. For mucosal 
vaccines, the most effective experimental mucosal adjuvants known 
today are the cholera toxin and E. coli lymphotoxin, which are able 
to induce a good systemic and mucosal immune response. However, 
they are also very toxic and not acceptable for human use [5] despite 
attempts to overcome this drawback [6,7]. Within this context, the use 
of probiotic lactic acid bacteria (LAB) as mucosal adjuvants emerges 
as a novel alternative to enhance the specific immune response. There 
is vast evidence showing that the main mechanism through which 
probiotics provide health benefits is the modulation of immune 
functions, an effect that is strain-dependent [8,9]. Lactobacillus casei 
CRL 431 is a probiotic as well as an immunobiotic [10] strain since 
it is able to activate the mucosal immune system [8,9,11]. Previous 
reports have shown that this lactobacillus was able to increase specific 
anti-pneumococcal IgA and IgG after a respiratory pneumococcal 
infection in a mouse model. In addition, pro-inflammatory TNF-α and 
regulatory IL-10 cytokines [11] increased when L. casei was preventively 
administered by the oral and nasal route [11,12]. In the development 
of vaccines, LAB were used mainly as antigen vehicles [13,14] while 
there are few studies concerning the use of non-recombinant strains 
as adjuvants in mucosal vaccine formulations. In this sense, it was 
demonstrated that nasal administration of live and heat-killed L. casei 
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Abstract
In this work we assessed the immune response induced by combinations of live (LcV) and heat-killed (LcM) 
Lactobacillus casei CRL 431 as adjuvants associated with pneumococcal protective A protein (PppA) in peripheral 
blood mononuclear cells (PBMCs). LcV, LcM and their combinations with PppA stimulated T, B and NK cells. Thus, all 
stimuli increased CD25 expression in T CD3 lymphocytes, highest activation being reached with the combinations of 
LcV or LcM with an antigen (PppA+LcV, PppA+LcM). Expression of CD19 B cells marker was significantly increased 
in almost all treatments compared with non-stimulated PBMCs, except for PppA. All treatments increased CD86 
expression in the LT population, while in B cells only LPS, PppA+LcV and PppA+LcM increased it. NK cells were 
significantly increased by LPS (P<0.05), PppA+LcM (P<0.01) and PppA+LcV (P<0.01) compared to non-stimulated 
PBMCs. PppA+LcV and PppA+LcM increased CD56 expression in both NKT and NK cells, while LcM expanded 
NKT population. Cytokine pattern analysis showed that LcV and LcM stimulated Th, Th2 and Th17 cytokines and 
exerted an important adjuvant effect when associated with PppA. Correlation with previous results obtained in animal 
models when the same experimental vaccine was nasally administered is discussed. Human PBMCs would be 
useful to evaluate the immune response of mucosal vaccines containing lactic acid bacteria associated with a 
specific antigen.
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CRL 431 associated with pneumococcal protective A protein (PppA) 
effectively prevented lung colonization in a pneumococcal respiratory 
infection and increased the survival of mice intraperitoneally 
challenged with the pathogens [15]. Animal models are very useful 
tools to study the effect of vaccines on the protection against human 
pathogens but the results obtained with them do not guarantee their 
effectiveness in human health. A recent report showed that previous 
diet supplementation with BB-12 or with L. casei 431 administered by 
the oral route effectively improved the immune function by increasing 
the systemic and mucosal immune response in volunteers before they 
received seasonal influenza vaccination [16]. No data are available with 
respect to the effect of immunobiotics strains associated with a specific 
antigen on cellular immunity, either from human studies or from “in 
vitro” assays in human cells. The aim of this work was to evaluate the 
immune response induced by experimental vaccines containing live or 
heat-killed lactobacilli as adjuvants associated with a pneumococcal 
antigen on cytokine production and cellular immunity in a human cells 
model (peripheral blood mononuclear cells: PBMCs) and to analyze 
the potential mechanism/s involved in this effect. On the other hand, 
in a previous work [15], the same vaccines administered nasally were 
evaluated in an animal model. Thus, correlation of results obtained “in 
vitro” and “in vivo” will be discussed in order to analyze the usefulness 
of PBMCs as an alternative to assess the effect of a mucosal vaccine 
on humans. Although PBMCs are a mixture of systemic immune cells, 
the immune response induced in them is more representative of the 
real situation of the body than the study of specific isolated mucosal 
cells. Moreover, mucosal vaccines are also required to provide systemic 
protection. 
Materials and Methods 
Microorganisms and culture conditions 
Recombinant E. coli-PppA was obtained in our laboratory and the 
development of this strain was described in a previous report from our 
work group [17]. From this strain rPppA protein was purified. The 
development of this strain, from which recombinant PppA (rPppA) 
was purified, was described in a previous report from our work group 
[17]. 
Lactobacillus casei CRL 431 (L. casei) [15,18], obtained from the 
CERELA culture collection, was cultured overnight at 37°C (final log 
phase) in Man-Rogosa-Sharpe broth (Oxoid), harvested and washed 
twice with sterile 0.01 M phosphate buffer saline (PBS), pH 7.2, 
and resuspended in PBS containing 20% glycerol. Aliquots of these 
suspensions were stored at -80°C until use. The number of live cells 
after freezing and thawing was determined by colony-forming unit 
(CFU) counting on MRS-C agar after 48 h incubation. 92-94% cells of 
L. casei were alive upon thawing and no significant differences were 
found during storage time (4 months). One fresh aliquot was thawed 
for every new experiment to prevent variability in the cultures between 
experiments. The bacterial suspension was adjusted to the desired 
concentration (106 cell/well) to stimulate PBMCs and this suspension 
constituted the live-cell suspensions: LcV. Heat-killed L. casei (LcM) 
was prepared by heating bacteria in a water bath at 80°C for 30 min and 
lack of bacterial growth was confirmed using MRS agar plates. 
Isolation and stimulation of PBMCs
PBMCs were isolated from the heparinized peripheral blood of 
four healthy volunteers (median age 28 years, range 25-33 years) after 
their written consent was obtained, as described in a previous report 
[19]. Briefly, PBMCs were isolated by centrifugation over a Ficoll 
density gradient (SIGMA, NJ, USA), washed with RPMI-1640 (Gibco, 
Invitrogen, Buenos Aires, Argentina) and adjusted to 1×106 cells/ml in 
RPMI-1640 supplemented with 10% fetal bovine serum (FBS) (Natacor, 
Córdoba, Argentina), 2 mM l-glutamine, 100 mg/ml streptomycin and 
100 U/ml penicillin (Sigma). PBMCs were incubated in 24-well flat-
bottomed polystyrene microtiter plates (Corning, GBO, Argentina) 
in the presence or absence of different stimulants in a humidified 
atmosphere of 5% CO2 at 37°C for 24 h. Final concentrations of either 
1×106 CFU/ml live and heat-killed cell suspensions, PppA (10 μg/ml) 
or combinations of LcV or LcM plus PppA were used as stimulants. 
Purified lipopolysaccharide (LPS) from Escherichia coli O111:B4 
(Sigma) was used to stimulate PBMCs at a concentration of 1 μg/ml as a 
positive control. Non-stimulated PBMCs were also evaluated as controls 
of basal cytokine production and cell-surface marker expression. All 
reagents were tested by the E-toxate test for LPS (Sigma) and shown to 
be below the detection limit (2 pg/ml).
Every stimulus was assayed in duplicate and each experiment was 
performed with PBMCs from four donors. Cell culture supernatants 
were collected by centrifugation, filtered using 0.22 μl filters that 
eliminate bacteria, fractionated in aliquots and stored at -20°C until 
cytokines were analyzed. PBMCs were harvested for cytometry analysis 
as described below.
Pneumococcal antigen 
rPppA was purified from E. coli-PppA [17] using a His-Bind 
purification kit (Novagen) and visualized by electrophoresis on 12% 
SDS-polyacrylamide gels, as previously described [17]. The reagent and 
the PppA solution were tested by the E-toxate test for LPS (Sigma) and 
shown to be below the limit of detection (2 pg/ml). rPppA concentration 
was determined by Bradford’s method and 10 ug of this protein was 
used in immunization protocols. This same concentration of PppA was 
employed in a previous report in an animal model [15].
PBMC surface phenotyping by flow cytometry 
To evaluate the effects of live or heat-killed L. casei, PppA and 
combinations of both on PBMC surface antigen expression, cells were 
removed gently from wells by scraping and stained with appropriate 
combinations of fluorescently labeled monoclonal antibodies (mAbs) 
that included: fluorescein isothiocyanate (FITC)-labeled anti-CD3, 
anti-CD19, anti-CD86; phycoerythrin (PE)-labeled anti-CD4, anti-
CD25 and peridinin chlorophyll-aprotein (PercP) anti-CD8. In 
addition, triple CD4-CD8 and CD3 mAbs were used when T cells were 
evaluated (all mAbs from BD Pharmigen). Cells were stained with 
labeled mAbs in PBS + 2% fetal bovine serum (PBS-FBS) for 30 min 
at 4°C, washed and re-suspended in ice-cold PBS-FBS. Then, cells were 
acquired by a Partec Past II flow cytometer (BD Bioscience) and data 
were analyzed with Flomax software.
Cytokine assays
Cytokine concentrations of supernatants were measured by human 
Th1/Th2 enzyme-linked immunosorbent assay (ELISA) Ready SET Go! 
Kit (BD Bioscience, San Diego, CA, USA), including interleukin (IL)-
2 and interferon (IFN)-γ as Th1-type and IL-4 and IL-10 as Th2-type 
cytokines. The IL-17 cytokine was also measured using the ELISA kit 
from e-Bioscience (BD Biosciences). The detection procedures were 
performed according to the manufacturer’s instructions. The sensitivity 
of the assays for each cytokine was as follows: 4 pg/ml for IL-2, IFN-γ 
and IL-17, and 2 pg/ml for IL-4 and IL-10.
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Statistical analyses 
Experiments were performed in triplicate and results were 
expressed as mean ± standard deviation (SD). Data were evaluated 
by one-way or two-way ANOVA tests. Tukey’s test (for pairwise 
comparisons of the mean values of the different groups) was used 
to test for differences between the groups. Significant difference was 
defined as P<0.05.
Results 
T- and B-cell surface marker expression and activation 
induced by experimental vaccine 
Both humoral and cellular immune responses are important 
components of the defense immune system in the struggle against 
S. pneumoniae. Thus, we studied the effect of live (LcV) or heat-
killed (LcM) L. casei in combination with a pneumococcal antigen 
on the expression of T and B surface markers. With respect to the T 
lymphocyte population, results showed that none of the stimuli assayed 
induced changes in the expression of cell surface marker CD3; thus, 
total T population in all treatments showed expression values similar 
to those of the control (RPMI) (Table 1). In addition, we determined 
whether the expression of CD4 (TCD4+ = helper T lymphocytes) 
or CD8 (TCD8+ = cytotoxic T lymphocytes) was modified. Results 
demonstrated that none of the stimuli assayed was able to increase 
CD4 or CD8 expression in PBMCs. In order to evaluate the effect of 
different stimuli on total B lymphocytes, we used CD19 as a marker of 
mature B cells. In contrast to T cells, CD19 expression was significantly 
increased in almost all the treatments compared with control, the only 
exception being the PppA group (Table 2). Activation of B and T cells 
after specific stimulation was evaluated by the expression of the CD86 
molecule in these cells. The CD86 molecule is expressed on activated 
B cells, T cells, dendritic cells and monocytes/macrophages. Analysis 
of CD86+CD3+ T cells and CD86+CD19 B cells (Table 1 and Table 
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Figure 1: Effect of live (LcV), heat-killed Lactobacillus casei (LcM), pneumococcal antigen (PppA), combinations of both Lc and PppA (PppA+LcV, 
PppA+LcM) and LPS on expression of surface markers CD56 and CD3 in peripheral blood mononuclear cells. A) Control and B) PppA+LcM are representatives 
dot-plot using anti-CD3 and anti-CD56 mAb, allowing identification of 3 cell subsets: CD3-CD56+ (NK cells), CD3+CD56+ (NK-T cells) and CD3+CD56- (T cells). 
Graphic indicates the percentage of cells for each of these subsets. Data are expressed as mean ± ds values of 4 healthy donors. Duplicate assays were performed 
for each donor and each stimulus. (*P<0.05, **P<0.01, ***P<0.001).
CD3+ CD4+ CD8+ CD3+CD86+ CD25+CD3+
Control 70.6 ± 205 44.1 ± 3.5 25.3 ± 1.2 0.76 ± 0.12a 1.60 ± 0.21a
LPS 71.7 ± 1.8 42.7 ± 5.7 25.3 ± 1.3 1.38 ± 0.15b 2.90 ± 0.90b
LcV 71.2 ± 2.4 45.2 ± 3.2 25.1 ± 1.1 0.96 ± 0.10c 3.10 ± 0.78b
LcM 69.5 ± 1.6 45.4 ± 4.2 24.1 ± 1.5 0.94 ± 0.07c 3.34 ± 0.67b
PppA 69.4 ± 3.5 45.1 ± 4.7 25.7 ± 1.3 0.89 ± 0.05c 2.69 ± 0.53b
PppA+LcV 71.0 ± 1.8 47.1 ± 2.1 26.2 ± 1.6 1.02 ± 0.02d 3.90 ± 0.84c
PppA_LcM 70.9 ± 2.2 46.4 ± 3.8 23.1 ± 1.8 0.99 ± 0.01d 3.67 ± 0.81c
Table 1: Surface cell markers in T human cells.
 CD19+ CD19+CD86+
Control 10±1,5 a 0.44±0.01 a
LPS 13±1,1 b 0.75±0.10 b
LcV 12,5±1,3 b 0.49±0.04 c
LcM 13,5±1,4 b 0.48±0.02 c
PppA 11,8±1,0 a 0.42±0.03 a
PppA+LcV 13,4±1,3 b 0.52±0.03 d
PppA+LcM 13,9±1,5 b 0.52±0.02 d
Expression of surface markers CD19 and CD86 induced by peripheral blood 
mononuclear cells stimulated with live (LcV), heat-killed Lactobacillus casei (LcM), 
pneumococcal antigen (PppA), combinations of both Lc and PppA (PppA+LcV, 
PppA+LcM), LPS and Control. (See Table 1 for details)
Table 2: Surface cell markers of B cells.
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2) showed that all treatments increased CD86 expression in the LT 
population, while in the LB population only LPS, PppA+LcV and 
PppA+LcM induced an increased expression of that marker. Overall, 
these results indicate that the experimental vaccines were able to induce 
the activation of T and B cells with expansion of B cells and that LcV or 
LcM exerted an adjuvant effect when combined with the pneumococcal 
antigen. Humoral immunity is an important component of the defense 
against pneumococci and B activation requires the cooperation of LT. 
Thus, in order to evaluate the antigen-primed specific T cells after 
stimulation, we studied the activation of T CD3+ cells by evaluating 
CD25 marker expression (Table 1). 1.6% of the non-stimulated CD3+ T 
cells expressed the surface CD25 marker while all the stimuli were able 
to induce an increase in CD25 expression on T lymphocytes. However, 
highest activation of CD3+ T cells was reached by the combinations of 
LcV and LcM with the pneumococcal antigen. These groups reached 
an increase in CD25 expression of above 100% compared with control 
PBMCs.
Evaluation of surface markers of NK cells 
NK cells are considered as a part of the innate immunity but they 
also represent a nexus between innate and adaptive immunity through 
the secretion of cytokines such as INF-γ and TNF-α. The CD56 marker 
was used to characterize this NK population by flow cytometry (Figure 
1). Results showed that surface marker CD56 expression that included 
total NK cells was significantly increased only by PBMC stimulation 
with LPS (P<0.05), PppA+LcM (P<0.01) and PppA+LcV (P<0.01) 
compared to control, while LcV and LcM tended to increase surface 
marker CD56 expression but no significant differences were found. 
In order to discriminate between NK and NKT cells, we evaluated 
CD56+CD3- (NK) and CD56+ CD3+ (NKT) cells. Stimulation with the 
combinations PppA+LcV and PppA+LcM increased CD56 expression in both NKT (CD3+CD56+) and NK (CD3-CD56+) cells, while LcM 
expanded NKT population in contrast with LPS, which expanded 
CD56+CD3- NK cells. LcV tended to expand this last population but 
no significant differences were found compared with the control group. 
Cytokine patterns induced by stimulation with experimental 
vaccines 
In order to evaluate the activation of T cells, the patterns of 
cytokine production of Th1 (IL-2, INF-γ), Th2 (IL-4, IL-10) and Th17 
(IL-17) induced by both LcV and LcM, pneumococcal antigen (PppA), 
probiotic plus PppA, LPS and RPMI (control) by PBMCs stimulation 
are shown in Figures 1, 2 and 3. Pro-inflammatory INF-γ production 
was increased by all stimuli but PppA+LcV and PppA+LcM induced 
significantly higher values than the other stimuli (Figure 2). In addition, 
PppA+LcM induced significantly higher INF-γ levels than PppA+LcV 
(P<0.01). The T helper type 1 (Th1) IL-2 cytokine was significantly 
increased when cells were stimulated with almost all stimuli compared 
with control, the only exception being the PppA group. T helper 
type 2 (Th2) IL-4 and IL-10 cytokine production was also evaluated. 
Stimulation of PBMCs “in vitro” resulted in the production of very low 
amounts of IL-4. Thus, control cells (RPMI) and PppA groups showed 
no production of this cytokine. In contrast, LPS, LcV, LcM, LcV+PppA 
and LcM+PppA were able to induce a significant increase in IL-4 levels: 
pg/ml: LPS=6.7*±1.2 (P<0.01); LcV=9.7*±1.3 (P<0.01); LcM=9.5*±1.6 
(P<0.001); LcV+PppA=17.1**±2 (P<0.001); LcM+PppA=16.9**±3 
(P<0.01). The induction of regulatory IL-10 cytokine was increased by 
all the stimuli except PppA (Figure 3). An interesting fact was that LcV 
induced higher IL-10 production than LcM (P<0.01) and this behavior 
was maintained when combinations with PppA were evaluated. The 
IL-17A cytokine pattern was also evaluated and results showed that all 
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Figure 2: Th1 cytokines production by peripheral blood mononuclear 
cells stimulated with live (LcV), heat-killed Lactobacillus casei (LcM), 
pneumococcal antigen (PppA), combinations of both (PppA+LcV, 
PppA+LcM), LPS and Control. Panel A, IL-2 production, Panel B, INF-γ 
production. Results are expressed as mean ± SD of duplicate measurements 
determined in four independent experiments. Tukey’s test was used to test for 
differences between the groups. Means in the figure with different letters (a–f) 
were significantly different (P<0.01).
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Figure 3: IL-10 production by peripheral blood mononuclear cells 
stimulated with live (LcV), heat-killed Lactobacillus casei (LcM), 
pneumococcal antigen (PppA), combinations of both (PppA+LcV, 
PppA+LcM), LPS and Control. (See Figure 2 for details).
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Figure 4: IL-17 production by peripheral blood mononuclear cells 
stimulated with live (LcV), heat-killed Lactobacillus casei (LcM), 
pneumococcal antigen (PppA), combinations of both (PppA+LcV, 
PppA+LcM), LPS and Control. (See Figure 2 for details).
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the stimuli tested induced increased levels of this cytokine compared 
with control (Figure 4). Overall, LcV, LcM and their combinations with 
PppA increased Th1, Th2 and Th17 cytokines while PppA only induced 
an increase in INF-γ and IL-17 levels. Live and heat-killed L. casei were 
able to stimulate Th1, Th2 and Th17 cytokines and exerted an important 
adjuvant effect when associated with the pneumococcal antigen.
Discussion 
The development of effective broad-coverage pneumococcal 
vaccines is an important challenge nowadays. The use of pneumococcal 
proteins, independently of serotypes, is the most promising alternative, 
although so far there are no licensed vaccines based on these antigens. 
Some relevant aspects to be considered in this respect are the route 
of immunization, the efficacy and immunogenicity of the vaccine 
and the adjuvants employed. Most vaccines are delivered through 
the parenteral route. However, mucosal vaccination has several 
benefits over the parenteral way: it is easy to administer, it can be 
administered through the same route of entry as pathogens, it makes 
self-administration possible and is able to induce the systemic and 
mucosal immune response. The nasal route is undoubtedly the better 
way to provide immunization against pathogens that enter the body 
through the respiratory tract and generally an appropriate immune 
response in the mucosal and systemic compartments is induced 
against specific antigens [5,20,21]. However, in contrast to parenteral 
immunization, mucosal immunizations require potent adjuvants to 
enhance immunogenicity. At present, numerous investigations aimed 
at selecting appropriate mucosal adjuvants are being conducted around 
the world [21,22]. However, only a few adjuvants have been accepted 
for use in human health and some of them have undesirable side effects 
[5,21]. Thus, safety is a crucial characteristic in the selection of potential 
mucosal adjuvants. Lactic acid bacteria are considered GRAS (Generally 
Recognized as Safe) microorganisms and their capacity to stimulate 
the immune system is amply documented, so that they are good 
candidates to be used as mucosal adjuvants. In previous reports, the 
immunostimulant properties of an inactivated recombinant lactococcus 
expressing PppA [18] and live/heat-killed Lactobacillus casei associated 
with PppA were demonstrated in mice [15]. The animal model allowed 
us to obtain crucial information about the mucosal adjuvant effect of 
dead and live Lactobacillus casei. However, the results obtained did 
not guarantee the same positive effect on the human immune system. 
In this work, the effect of the combination of a pneumococcal antigen 
with immunobiotic lactobacilli on human immunity was evaluated 
using primary cultures of human PBMCs. Different immune cells were 
evaluated after stimulation with experimental vaccine formulations. 
T cells play a crucial role in the mechanisms involved in the humoral 
and cellular specific immune response induced after vaccination. In the 
PBMCs model, combinations of LcV and LcM with PppA were able to 
induce an increase in the expression of the surface marker CD25. CD25 
(IL-2Rα) is a marker expressed principally on activated T cells and Th1, 
Th2 and Th17 cytokines production induced by almost all stimuli was 
also a clear evidence of T cells activation. On the other hand, previous 
reports have shown overall agreement with CD25 and proliferation 
assays when a recall specific antigen was used [23,24]. In our model, 
CD3, CD4 and CD8 markers did not increase their expression when 
PBMCs were stimulated. It seems likely that a longer stimulation period 
is necessary to induce a significant clonal expansion of T cells compared 
with control without stimulation [25].
With respect to CD19+ B cells, these were increased with almost 
all stimuli except PppA. Highest CD19 expression was obtained by 
stimulation with PppA+LcV and PppA+LcM, while LcV and LcM were 
also able to increase the expression of this marker, with no significant 
differences between them. In addition, surface marker CD86 expression 
was increased by all stimuli in T cells while in B cells the stimulation 
with PppA was not able to increase CD86 expression. T-cell-B-cell 
cooperation is a crucial event in the induction of the specific immune 
response against protein antigens and both LcV and LcM exerted a 
stimulant effect on the activation of both T and B cells. The humoral 
immune response plays a fundamental role in vaccination for the 
generation of specific antibodies. In a previous report, PppA+LcV and 
PppA+LcM combinations, nasally administered in a mouse model, 
were able to induce high IgG and IgA anti-PppA levels in systemic and 
mucosal compartments and these antibodies remained elevated up to 
and including day 74 [15]. In the “in vitro” model used in this work, 
IL-4 production showed higher levels than the control groups in all 
cases, except for PppA. IL-4 is a pleiotropic cytokine that plays a key 
role in the activation of B cells resulting in the stimulation of humoral 
immunity. In addition, it is important in the generation of Th2 effector 
cells from naïve CD4 T cells [26]. Moreover, IL-10, a regulatory cytokine 
involved in the stimulation of the humoral response, was also increased 
by PppA+LcV, PppA+LcM, LcV and LcM. Monocytes, macrophages, 
regulatory T and T helper (Th) cells are the major sources of IL-10 
but other cell types, including natural killer (NK) cells, dendritic cells, 
cytotoxic T cells and B cells, also produce this cytokine [27,28]. IL-10 
is typically an anti-inflammatory cytokine with regulatory functions 
of immune cells but it also plays a positive role in the promotion of 
humoral immunity since it enhances proliferation and differentiation 
of B cells, prevents their apoptosis and stimulates MHCII expression in 
these cells [29]. In addition, IL-10 stimulates NK activity and increases 
the IL-2-induced proliferation of CD56+ cells [30]. The stimulation of 
NK by live and heat-killed lactobacilli in “in vitro” studies was reported. 
Thus, live Lactobacillus casei Shirota (LcS) was able to enhance NK 
activity in PBMCs [31]. Besides, heat-killed LcS stimulated IL-10, 
IL-12 and TNF-α and promoted NK cells activity [32]. In our model, 
combinations of LcV+PppA, LcM+PppA, LcV and LcM increased 
IL-2 induction; thus, this fact, together with IL-10 increase, would 
be involved in NK stimulation. Numerous studies have demonstrated 
that cell components of lactobacilli such as LTA (lipoteichoic acid), 
lipopeptides, cell wall peptidoglycans [33,34] through TLR2 in 
conjunction with TLR6 or TLR1 [35] and DNA [36,37] through TLR9 
are able to stimulate the immune system. A recent report [38] has 
shown that NKT cells are required for protective responses against 
Streptococcus pneumoniae and other Gram positive pathogens. LcM 
increased this population in PBMCs and this fact would be beneficial 
for the development of a mucosal vaccine against pneumococci. In 
addition, LcV increased NKT population, although not significantly, 
with respect to the control group. However, both LcV+PppA and 
LcM+PppA combinations were able to increase NKT population. 
The differences observed between LcV and LcM with respect to NKT 
(CD56+-CD3+) and NK cells (CD56+) would be due to alterations 
on the surface of Lactobacillus casei after it was heat killed; however, 
further studies are necessary to elucidate this point and to determine the 
mechanisms involved in this effect. On the other hand, both heat-killed 
and live lactobacilli as well as their respective combinations with the 
pneumococcal antigen stimulated IL-2 induction in PBMCs. This Th1 
cytokine is very important in vaccination because it would influence 
the proliferation and maintenance of memory cells [39,40], a desirable 
condition in vaccines with long-term efficacy. With respect to INF-γ, 
its patterns showed increased levels when PBMCs were stimulated with 
LcM and LcV, LcM reaching higher values than LcV. Th1 and NK cells 
are a source of INF-γ, which plays an important role in the neutrophil-
mediated host protective responses against pneumococcal infection 
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promoted by NKT cells [41-43]. In addition, the combinations of PppA 
with LcV and LcM induced higher values of IL-17 cytokines. IL-17A-
secreting CD4+ T cells (Th17) mediate resistance against mucosal 
colonization by S. pneumoniae and play an important role in the 
clearance of pathogens in a mouse model [44,45]. In addition, humans 
lacking Th17 cells due to genetic mutation are highly susceptible to 
mucosal infections by S. pneumoniae [46]. Scientific evidence in animal 
and human cell models indicates that Th17 cells are implicated in the 
defense against human pathogens. Recent reports have demonstrated 
that pneumococcal antigens able to activate Th17 cells are effective 
as mucosal immunogens that can afford protection to mice against S. 
pneumoniae colonization [45,47]. This protection occurs in a CD4+T 
cell and IL-17 dependent manner [45,47]. IL-17 induction is a desirable 
characteristic in the design of pneumococcal vaccines and both 
LcV+PppA and LcM+PppA combinations were able to induce this 
cytokine. However, the use of dead lactobacilli as adjuvants in mucosal 
vaccines is undoubtedly an advantage over other adjuvants because 
it would allow the safe administration of potential vaccines even in 
the case of immuno compromised hosts and elderly people without 
the risks associated with live bacteria [48]. On the other hand, some 
works have shown that “in vitro” assays do not necessarily correlate 
with clinical outcome [49,50]. In contrast, the results obtained in this 
paper with respect to the activation of Th1 and Th2 and also Th17 cells 
did correlate with the results obtained “in vivo” using a pneumococcal 
infection model and PppA+LcM and PppA+LcV combinations as a 
potential nasal vaccine [15]. To the best of our knowledge, this is the 
first work that evaluates the effect of a live or heat-killed lactic acid 
bacteria associated with a pneumococcal antigen in a human cell model 
and correlates the results with the nasal experimental vaccine evaluated 
in a mouse model. Adjuvant capacity is strain-dependent and specific 
antigens and their characteristics can induce different responses. 
Further studies are under way to evaluate the adjuvanticity of other 
lactic acid bacteria associated with viral and bacterial antigens. On the 
other hand, the immune response induced after vaccination depends 
on a multiplicity of factors such as nutritional status, preexisting 
immunity, genetic and environmental factors and geographical location 
of the host. Therefore, “in vitro” assays using human PBMC cultures that 
implicitly include the above aspects would be a useful model to evaluate 
an experimental mucosal vaccine that includes a lactic acid strains as 
adjuvant associated with specific antigens. The immune response of 
PBMCs after stimulation is more likely to mimic an “in vivo” response 
in human individuals than cell lines or isolated mucosal cells.
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